AC Immune(ACIU) Newsfilter·2024-08-06 11:00Core Insights - AC Immune has reported strong financial results for Q2 2024, highlighting a partnership with Takeda for ACI-24.060, which includes an upfront payment of 2.1 billion [1][3][6] - The company is advancing its clinical trials, with the ABATE Phase 2 trial for ACI-24.060 in Alzheimer's disease on track and the VacSYn Phase 2 trial for ACI-7104.056 in Parkinson's disease expected to provide interim data in H2 2024 [1][5][6] - AC Immune's cash position is robust, with a balance of CHF 175.2 million, providing sufficient runway for three years of operations [1][6] Financial Highlights - The company recorded CHF 0.7 million in contract revenues for Q2 2024, a significant increase from nil in the prior period, primarily due to the agreement with Takeda [6][13] - Research and development expenses rose to CHF 17.1 million in Q2 2024 from CHF 13.7 million in the same period of 2023, driven by increased clinical activities [6][14] - The net loss for the period was CHF 22.8 million, compared to a net loss of CHF 16.8 million in Q2 2023, reflecting higher operating expenses [6][15] Clinical Development Updates - Enrollment in the ACI-24.060 ABATE Phase 2 trial for Alzheimer's disease is progressing as planned [2][3] - The company has completed regulatory toxicology studies for its anti-TDP-43 monoclonal antibody candidate, enabling the IND filing [3] - ACI-19764, a potent NLRP3 inhibitor, has shown promising preclinical results and is expected to file an IND soon [3][4] Strategic Partnerships and Innovations - The partnership with Takeda is expected to enhance AC Immune's capabilities in developing best-in-class immunotherapies targeting Abeta [2][3] - The morADC platform, combining SupraAntigen® and Morphomer® technologies, is showing promise in preclinical models for neurodegenerative diseases [2][3] - The company is also developing a first-in-class TDP-43 PET tracer, [18F]ACI-19626, for monitoring TDP-43 aggregates [4]